{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-027621","form_type":"8-K","ticker":"TNXP","cik":"0001430306","company_name":"Tonix Pharmaceuticals Holding Corp.","filed_at":"2026-06-08T11:05:29+00:00","discovered_at":"2026-06-08T11:10:01.258858+00:00","generated_at":"2026-06-08T11:12:45.554253+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Tonix secures second GPO agreement for TONMYA, expanding commercial coverage to ~52M lives","bullets":["Second GPO agreement effective June 1, 2026 adds ~17M US commercial lives (~10% of total).","Total commercial coverage now ~52M lives (~29% of US commercial lives); first GPO covered ~35M from May 1.","TONMYA covered under Medicaid in most states (~75M beneficiaries); Medicare discussions ongoing.","TONMYA (cyclobenzaprine HCl sublingual tablets) approved by FDA Aug 2025 as first new fibromyalgia treatment in over 15 years."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-027621","json":"https://secwatch.observer/filing/0001493152-26-027621.json","markdown":"https://secwatch.observer/filing/0001493152-26-027621.md","text":"https://secwatch.observer/filing/0001493152-26-027621.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1430306/000149315226027621/0001493152-26-027621-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1430306/000149315226027621/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T11:12:45.554253+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}